We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+15.41%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$6.93B
AUM Growth
+$1.24B
(+22%)
Cap. Flow
+$454M
Cap. Flow
% of AUM
6.54%
Top 10 Holdings %
Top 10 Hldgs %
16.4%
Holding
1,110
New
146
Increased
497
Reduced
266
Closed
160
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVR
NVR
|
+$34.9M |
| 2 |
SBA Communications
SBAC
|
+$31.5M |
| 3 |
Lennox International
LII
|
+$29.1M |
| 4 |
McKesson
MCK
|
+$24.8M |
| 5 |
Cable One
CABO
|
+$23.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$55.8M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$52.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$42.5M |
| 4 |
Intuitive Surgical
ISRG
|
+$35.5M |
| 5 |
XLNX
Xilinx Inc
XLNX
|
+$33.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.87% |
| 2 | Financials | 16.58% |
| 3 | Consumer Discretionary | 13.8% |
| 4 | Industrials | 12.36% |
| 5 | Healthcare | 10.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Alpha and Omega Semiconductor
AOSL
$922M
| $494K | 0.01% |
42,891
-14,241
| -25% | -$157K |
|
777
Spero Therapeutics
SPRO
$68.3M
| $490K | 0.01% |
38,222
+22,782
| +148% | +$242K |
|
|
SFS
778
DELISTED
Smart & Final Stores, Inc.
SFS
| $485K | 0.01% |
+98,198
| New | +$595K |
|
|
PETX
779
DELISTED
Aratana Therapeutics, Inc.
PETX
| $484K | 0.01% |
134,396
+117,296
| +686% | +$508K |
|
780
Cogent Biosciences
COGT
$6.91B
| $479K | 0.01% |
27,269
+14,970
| +122% | +$256K |
|
|
STEL
781
DELISTED
Stellar Bancorp
STEL
| $476K | 0.01% |
+14,652
| New | +$473K |
|
|
EMKR
782
DELISTED
Emcore Corp
EMKR
| $476K | 0.01% |
13,052
+2,170
| +20% | +$92.4K |
|
783
Provident Financial Services
PFS
$3.11B
| $467K | 0.01% |
18,029
| – | – |
|
784
Norfolk Southern
NSC
$77.1B
| $462K | 0.01% |
2,470
-3,750
| -60% | -$649K |
|
785
Foster
FSTR
$443M
| $458K | 0.01% |
24,327
+11,876
| +95% | +$211K |
|
786
Lincoln National
LNC
$7.88B
| $450K | 0.01% |
+7,660
| New | +$454K |
|
|
ISEE
787
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $448K | 0.01% |
317,947
+80,400
| +34% | +$112K |
|
|
CTO
788
CTO Realty Growth
CTO
$744M
| $446K | 0.01% |
+27,851
| New | +$451K |
|
789
Astec Industries
ASTE
$1.29B
| $444K | 0.01% |
+11,749
| New | +$439K |
|
790
First Commonwealth Financial
FCF
$2.12B
| $442K | 0.01% |
35,100
| – | – |
|
|
CALA
791
DELISTED
Calithera Biosciences, Inc
CALA
| $442K | 0.01% |
3,278
-245
| -7% | -$25.7K |
|
792
Fabrinet
FN
$16.9B
| $438K | 0.01% |
8,357
-17,883
| -68% | -$974K |
|
|
SURF
793
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $437K | 0.01% |
91,600
+56,466
| +161% | +$278K |
|
794
Ribbon Communications
RBBN
$359M
| $436K | 0.01% |
+84,585
| New | +$453K |
|
|
JAX
795
DELISTED
J. Alexander's Holdings, Inc.
JAX
| $435K | 0.01% |
44,271
+11,767
| +36% | +$108K |
|
|
HONE
796
DELISTED
HarborOne Bancorp
HONE
| $434K | 0.01% |
45,324
+3,052
| +7% | +$27.4K |
|
|
EPZM
797
DELISTED
Epizyme, Inc
EPZM
| $434K | 0.01% |
35,050
-73,325
| -68% | -$820K |
|
798
James River Group Holdings
JRVR
$217M
| $429K | 0.01% |
10,712
-8,210
| -43% | -$322K |
|
|
FBMS
799
DELISTED
The First Bancshares, Inc.
FBMS
| $426K | 0.01% |
13,788
+900
| +7% | +$28.4K |
|
800
Prosperity Bancshares
PB
$8.69B
| $424K | 0.01% |
6,140
-34,055
| -85% | -$2.43M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q1 2019 Portfolio in Review
As of Q1 2019, Jacobs Levy Equity Management held 1,110 positions worth $6.93B, up 22% from $5.69B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Jacobs Levy Equity Management deployed $454M of net new capital in Q1 2019, opening 146 new positions and adding to 497 existing holdings. Its largest new stake was AbbVie: 282,010 shares worth $22.7M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $52.7M trimmed.
- Jacobs Levy Equity Management's largest Q1 2019 buy was AbbVie: 282,010 shares worth $22.7M.
- Jacobs Levy Equity Management added most to NVR in Q1 2019, an estimated $34.9M increase.
- Jacobs Levy Equity Management's biggest Q1 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $52.7M.
- Jacobs Levy Equity Management fully exited Celgene Corp in Q1 2019, selling an estimated $55.8M.
- Jacobs Levy Equity Management's ten largest holdings make up 16% of its $6.93B portfolio in Q1 2019.
- Jacobs Levy Equity Management opened 146 new positions and closed 160 in Q1 2019.
- Jacobs Levy Equity Management's portfolio value rose 22% quarter-over-quarter to $6.93B.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.